Fundamental Data for IMCL

IMCLONE SY(NSDQ:IMCL)

ImClone Systems Incorporated is advancing oncology care by developing a portfolio of targeted biologic treatments, which address the unmet medical needs of patients with a variety of cancers. The Company''s three programs include growth factor blockers, cancer vaccines and anti-angiogenesis therapeutics. ImClone''s strategy is to become a fully integratedbiopharmaceutical company, taking its development programs from the research stage to the market. (PRESS RELEASE)

# Employees: 1128

Address: 180 Varick Street,New York,NY,USA

Phone: 212-645-1405

Fax: 212-645-2054

Website: www.imclone.com

Email: ir@imclone.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Ana I. Stancic (Sr. V. P.; Fin.)

Andrew G. Bodnar (Dir.)

John A. Fazio (Dir.)

Alexander J. Denner (Chmn.; Exec. Comit. of the Board; Dir.)

Carl C. Icahn (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2008

Next Earnings Date(Expected): 1/22/2009

Mean EPS (Next Qtr): $0.26

Mean EPS (Year): $1.17

Mean Estimate(Long Term): $24.00

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 7

Shares Performance

Period	IMCL	Compare to S&P
YTD	-0.01 %	-0.01 %
4 Weeks	-0.01 %	-0.01 %
12 Weeks	-0.01 %	-0.01 %

Shares Information

Analyst Coverage: Y

Avg Volume: 1656436

Shares Outstanding: 88M

Market Cap: ($0.01)M

52 Week High: $69.99

52 Week Low: ($0.01)

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 10/16/2000 IMCL split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: -164.52 %

EPS Growth in Last Year: -154.05 %

Sales Growth in Last Quarter: -0.87 %

Sales Growth in Last Quarter: 11.87 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: -0.010